The purpose of our study was (i) to evaluate the impact of all-trans retinoic acid (ATRA)
given as adjunct to chemotherapy and (ii) to compare second consolidation vs maintenance …

All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients
with relapsed or refractory Page 1 All trans retinoic acid in combination with intermediate-dose …

The aim of this clinical trial was to evaluate the impact of all-trans retinoic acid (ATRA) in
combination with chemotherapy and to assess the NPM1 status as biomarker for ATRA …

Background In a previous randomized trial, AML HD98B, we showed that administration of
all-trans retinoic acid in addition to intensive chemotherapy improved the outcome of older …

BACKGROUND The survival of older patients with acute myeloid leukemia has not
improved. Few clinical trials have been available for older patients who are not considered …

Thirty-three patients with'poor prognosis' acute myeloid leukemia, no longer suitable for
aggressive chemotherapy, were treated with daily oral all-trans retinoic acid (45 mg/m2) …

In this Phase 2 study, we evaluated the efficacy of combination of 5-azacitidine (AZA),
valproic acid (VPA), and all-trans retinoic acid (ATRA) in patients with high-risk acute …

The outcome of patients with acute myeloid leukemia who are older than 60 years has
remained poor because of unfavorable disease characteristics and patient-related factors …

Therapeutic results in elderly patients with acute promyelocytic leukemia (APL) have been
generally reported as less effective than for younger patients. Patients 60 years or older with …

Background: All-trans retinoic acid (ATRA) is mandatory in the treatment of acute
promyelocytic leukaemia (APL). Experimental studies suggest that ATRA can induce …